Sign inJoin waitlistJoin the waitlist

Alan Skarbnik

Physician · Presbyterian Hospital

Credentials: · · · · · ·

History

Presbyterian Hospital
2021–Present

City of Hope National Medical Center
2013–2014
Hematology and Medical Oncology
Fox Chase Cancer Center
2010–2013
SAINT LUKES ROOSEVELT HOSPITAL
2007–2010
Faculty of Medicine of the University of São Paulo
1999–2003

Research

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3…
The Lancet · 2020 · 554 citations
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Haematologica · 2018 · 406 citations
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Blood · 2018 · 298 citations

Chaitra Ujjani
21 papers
Lindsey Roeker
21 papers · 12 as a fellow
Anthony Mato
20 papers
Stephen Schuster
20 papers
Mazyar Shadman
19 papers
Nicole Lamanna
19 papers
Brian Hill
18 papers
Paul Barr
18 papers
Danielle Brander
17 papers
John Allan
16 papers
Andre Goy
15 papers
JP
John Pagel
14 papers

Clinical trials

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Site PI · Recruiting · Phase 3
Eastern Cooperative Oncology Group
2025–2075
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Site PI · Recruiting · Phase 2
Allogene Therapeutics
2024–2032